Her2-low/ HRR proficient early triple negative breast cancer is characterized by good prognosis

被引：0
|
作者：
Pellegrino, B. [1 ]
Tornali, C. [2 ]
Lazzarin, A. [3 ]
Cotelli, B. [2 ]
Ingallinella, A. [2 ]
Campanini, N. [4 ]
Tommasi, C. [5 ]
Coriano, M. [6 ]
Serra, O. [7 ]
Michiara, M. [8 ]
Boggiani, D. [9 ]
Schirone, A. [10 ]
Casarini, C. [11 ]
Cretella, E. [12 ]
Zoppoli, G. [13 ,14 ]
Lambertini, M. [15 ]
Botosso, M. [16 ]
Cortesi, L. [17 ]
Silini, E. M. [18 ]
Musolino, A. [19 ]
机构：
[1] Osped Maggiore Parma, Oncol Dept, Parma, Italy
[2] Univ Parma, Oncol, Parma, Italy
[3] Univ Parma, Med Oncol Dept, Parma, Italy
[4] Univ Parma, Fac Med & Chirurg, Pathol, Parma, Italy
[5] Univ Parma, Fac Med & Chirurg, Med Oncol & Breast Unit, Parma, Italy
[6] Azienda Osped Univ Parma, Oncol, Parma, Italy
[7] Univ Parma, Fac Med & Chirurg, Oncol, Parma, Italy
[8] Osped Maggiore Parma, Oncol, Parma, Italy
[9] Univ Hosp Parma, Oncol, Parma, Italy
[10] Arcispedale SantAnna AOU Ferrara, Med, Ferrara, Italy
[11] Nuovo Osped Sassuolo, Oncol, Sassuolo, Italy
[12] Osped Cent Bolzano ASDAA SABES, Oncol Dept, Bolzano, Italy
[13] Univ Genoa, Dept Internal Med, Genoa, GE, Italy
[14] Osped Policlin San Martino IRCCS, DiMI, Genoa, GE, Italy
[15] IRCCS AOU San Martino, IST Ist Nazl Ric Canc, Oncol, Genoa, Italy
[16] IOV Ist Oncol Veneto IRCCS, Oncol, Padua, Italy
[17] Azienda Osped Univ Policlin Modena, Haematol & Oncol Dept, Modena, Italy
[18] Univ Parma, Pathol, Parma, Italy
[19] Univ Parma, Fac Med & Chirurg, Dept Med, Parma, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
269P
引用
收藏
页码：S328 / S329
页数：2
相关论文
共 50 条
  • [31] UPDATE ON TRIPLE-NEGATIVE BREAST CANCER: THE GOOD PROGNOSIS
    Sakhri, S.
    Hamza, K.
    Kamoun, S.
    Houcine, Y.
    Karima, T.
    Bouhani, M.
    Bettaib, I.
    Driss, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A306 - A306
  • [32] Biology and Treatment of HER2-Low Breast Cancer
    Nicolo, Eleonora
    Tarantino, Paolo
    Curigliano, Giuseppe
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 117 - 132
  • [33] Is HER2-low a biologically distinct breast cancer (BC) subtype? Prognosis and pathological complete response rate after neoadjuvant treatment (NAT) in early breast cancer (BC) HER2 negative
    Gil-Torralvo, Ana
    Rodriguez, Yeray
    Falcon, Alejandro
    Morales, David
    Cejuela, Monica
    Miras, Isabel
    Amerigo, Marta
    Ruiz-Borrego, Manuel
    Bayo, Juan
    Bofill, Francisco Javier Salvador
    CANCER RESEARCH, 2024, 84 (09)
  • [34] HER2-Low Breast Cancer: a New Subtype?
    Chiara Corti
    Federica Giugliano
    Eleonora Nicolò
    Paolo Tarantino
    Carmen Criscitiello
    Giuseppe Curigliano
    Current Treatment Options in Oncology, 2023, 24 : 468 - 478
  • [35] Clinical Significance of HER2-low Breast Cancer
    Zaiem, Fadi
    AbuJamea, Asem
    Kheil, Mira
    Numi, Anna
    Abbas, Omar
    Awada, Sanaa
    Almsaddi, Ragad
    Al-Juburi, Saleh
    Larson, Lauren
    Jain, Deepti
    AlSaghir, Maya
    Jang, Hyejeong
    Kim, Seongho
    Bandyopadhyay, Sudeshna
    Jaiman, Sunil
    Ali-Fehmi, Rouba
    CANCER RESEARCH, 2024, 84 (09)
  • [36] HER2-low breast cancer: where are we?
    Molinelli, Chiara
    Jacobs, Flavia
    Marchio, Caterina
    Pitto, Francesca
    Cosso, Maurizio
    Spinaci, Stefano
    de Azambuja, Evandro
    Schettini, Francesco
    Agostinetto, Elisa
    Lambertini, Matteo
    BREAST CARE, 2022, 17 (06) : 533 - 544
  • [37] Epidemiology of HER2-low breast cancer in Lithuania
    Cesas, A.
    Poskiene, L.
    Valkiuniene, R. B.
    Radvinskiene, L.
    Lege, I.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 103 - 104
  • [38] HER2-Low Breast Cancer: a New Subtype?
    Corti, Chiara
    Giugliano, Federica
    Nicolo, Eleonora
    Tarantino, Paolo
    Criscitiello, Carmen
    Curigliano, Giuseppe
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (05) : 468 - 478
  • [39] HER2-Low Breast Cancer: Now and in the Future
    Kang, Sora
    Kim, Sung-Bae
    CANCER RESEARCH AND TREATMENT, 2024, 56 (03): : 700 - 720
  • [40] A rapid, non-invasive test to determine HER2-low status in triple negative breast cancer (TNBC) patients
    Cook, Daniel
    Patel, Snehal
    Whitman, John
    Hobbs, Nicole
    Lopez-Ramos, Dorys A.
    Pfeiffer, John
    Peterson, Joseph
    Pandey, Tushar
    Antony, Anuja K.
    Cole, John
    CANCER RESEARCH, 2023, 83 (07)
12345